Helen L. Bernie, DO, MPH, highlights 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting.
In this video, Helen L. Bernie, DO, MPH, discusses 4 studies in sexual dysfunction being presented at the 2023 American Urological Association Annual Meeting in Chicago, Illinois. Bernie is director of Sexual and Reproductive Medicine at Indiana University, Indianapolis and assistant professor of urology at the Indiana University School of Medicine.
The following abstracts were previewed:
1. LBA01-12 (Ledesma et al): Platelet rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind, placebo controlled clinical trial
2. MP79-04 (Best et al): Stem-cell, shockwave, and platelet rich plasma therapy for the treatment of erectile dysfunction and Peyronie's disease: a survey of clinics from across the US
3. MP79-11 (Goldstein et al): A sham-controlled randomized trial of low intensity shockwave therapy for erectile dysfunction
4. PD42-02 (Barham et al): Partial component exchange of a non-infected IPP is associated with a higher complication rate
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.